- $43.00m
- -$69.43m
- $9.85m
- 34
- 38
- 43
- 31
Annual income statement for Kronos Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 6.29 | 9.85 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 58 | 151 | 137 | 128 | 103 |
| Operating Profit | -58 | -151 | -137 | -122 | -92.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -88.4 | -151 | -133 | -113 | -86.1 |
| Net Income After Taxes | -88.4 | -151 | -133 | -113 | -86.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -88.4 | -151 | -133 | -113 | -86.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -88.4 | -151 | -133 | -113 | -86.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.64 | -2.76 | -2.37 | -1.87 | -0.943 |
| Dividends per Share |